Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 2/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556890 | 0.83 | REN (0.56) | ERAP2ERAP1LNPEP | |
| SCHEMBL19982696 | 0.81 | ERAP2 (0.65) | ERAP2ERAP1LNPEPANPEPMMP3 | |
| SCHEMBL14122328 | 0.77 | MMP2 (0.62) | ERAP2ERAP1LNPEPMMP8MMP2 | |
| SCHEMBL14122732 | 0.77 | MMP2 (0.62) | ERAP2ERAP1LNPEPMMP8MMP2 | |
| SCHEMBL14232807 | 0.77 | MMP2 (0.62) | ERAP2ERAP1LNPEPMMP8MMP2 | |
| SCHEMBL6867825 | 0.77 | MMP2 (0.62) | ERAP2ERAP1LNPEPMMP8MMP2 | |
| SCHEMBL6868936 | 0.77 | MMP2 (0.62) | ERAP2ERAP1LNPEPMMP8MMP2 | |
| SCHEMBL14381163 | 0.76 | LTA4H (0.59) | MMP8MMP2MMP9MMP12MMP14 | |
| SCHEMBL5558796 | 0.76 | NPY4R (0.42) | ERAP2ERAP1LNPEPANPEPNPY4R | |
| SCHEMBL14232887 | 0.75 | MMP2 (0.65) | ERAP2ERAP1LNPEPMMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | ERAP2 1226/4885ERAP1 1012/4885LNPEP 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.